NASDAQ · Biotechnology

TCRX (TCRX) Stock

$0.79 +3.94% NASDAQ: TCRX Healthcare

Valuation

MetricValue
Price$0.79
Market Cap$48.45M
P/E Ratio-0.99
P/B Ratio0.49
P/S Ratio6.65
EPS (TTM)$-1.00
52-Week High$2.57
52-Week Low$0.74
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-105.69%
ROA-56.77%
ROCE-110.57%
Gross Margin-1360.00%
Operating Margin-1360.00%
Net Margin-13.61%
Debt/Equity0.62
Current Ratio8.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$10.0M$14.0M$21.0M$3.0M$10.0M
Operating Profit$-49.0M$-67.0M$-93.0M$-135.0M$-136.0M
Net Profit$-49.0M$-66.0M$-89.0M$-127.0M$-130.0M
EPS$-2.03$-2.74$-1.36$-1.14$-1.00
Op Margin-479.6%-492.3%-444.0%-4787.7%-1315.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$188.0M$199.0M$272.0M$371.0M$229.0M
Total Liabilities$27.0M$100.0M$121.0M$130.0M$106.0M
Cash$161.0M$120.0M$133.0M$179.0M$152.0M
Borrowings$6.0M$86.0M$92.0M$97.0M$94.0M

Latest News

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference GlobeNewswire · Jun 24, 2026 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT Newswires · Jun 22, 2026 TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation GlobeNewswire · Jun 22, 2026 Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies Business Wire · Jun 3, 2026 TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss Insider Monkey · Jun 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-49.0M$-67.0M$-61.0M$-111.0M$-135.0M
Investing Cash Flow$-20.0M$-8.0M$-64.0M$-56.0M$105.0M
Financing Cash Flow$0$0$93.0M$160.0M$-1.0M
Net Cash Flow$131.0M$-41.0M$13.0M$45.0M$-26.0M
Free Cash Flow$-59.0M$-71.0M$-65.0M$-115.0M$-140.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-205.71%
Quick Ratio6.65
Interest Coverage-45.33
Return 1Y-48.02%
Return 3Y-56.40%
Return 5Y-91.24%

Ownership

Insiders Held0.20%
Institutions Held59.46%
Institutions Float Held59.58%
Institutional HolderSharesReport Date
Lynx1 Capital Management Lp8,019,1482026-03-31
BVF Inc.5,564,2902026-03-31
Baker Bros. Advisors, LP2,784,7922026-03-31
Vanguard Capital Management LLC2,154,2562026-03-31
Blackrock Inc.1,840,9522026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About TCRX

TCRX is led by CEO Gavin MacBeath, employs 200 people, headquartered in US, publicly traded since 2021.

TCRX stock trades at $0.79 with a market capitalization of $48.45M. The stock is valued at a price-to-earnings (P/E) ratio of -0.99, price-to-book of 0.49, price-to-sales of 6.65. Over the past 52 weeks the stock has ranged between $0.74 and $2.57, and currently trades 69.3% below its 52-week high.

On profitability, TCRX generates a return on equity (ROE) of -105.69%, return on capital employed of -110.57%, an operating margin of -1360.00%, a net profit margin of -13.61%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides